retatrutide triple agonist gip glp-1 glucagon phase 3 2025 The data just dropped — and is rewriting what's possible in obesity medicine. 🧬 TRIUMPH-1 just released results, and the numbers are unlike anything we've seen from a medication: What Is Retatrutide? The Triple

All Day

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

20122014 Expanded Therapeutic Options The approvals of Qsymia, Belviq, Contrave, and Saxenda broadened the treatment landscape and reinforced obesity as a chronic disease requiring evidence-based medical management

Find out if GLP-1 drugs is covered by Humana, typical copay ranges, prior-auth rules, and affordable alternatives

While these agents are not recommended during pregnancy, their use in the preconception, periconception, and postpartum periods is increasing